These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21538429)

  • 41. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

  • 42. [Peginterferon alpha-2a and ribavirin for treating chronic hepatitis C patients with persistent normal aminotransferase levels].
    Jiang TJ; Fan R; Xie YX; Zhao P; Zhang X; Zhao M; Zhou ZP; He J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Apr; 16(4):307-8. PubMed ID: 18423159
    [No Abstract]   [Full Text] [Related]  

  • 43. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A 72 week follow-up study of chronic hepatitis C patients treated with peginterferon alfa-2b and ribavirin].
    Yu SL; Zhang ZH; Lv H; Zhang QG; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2007 Mar; 15(3):231. PubMed ID: 17407724
    [No Abstract]   [Full Text] [Related]  

  • 46. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
    Marcellin P; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Serfaty L; De Backer K; Van Heeswijk R; Luo D; Picchio G; Beumont M
    Gastroenterology; 2011 Feb; 140(2):459-468.e1; quiz e14. PubMed ID: 21034744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of re-treatment by peginterferon alpha-2a and ribavirin in a child with hepatitis C.
    Nishimata S; Tsutsumi N; Suzuki S; Nagao R; Kashiwagi Y; Kawashima H
    J Infect Chemother; 2014 Jul; 20(7):443-5. PubMed ID: 24793175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Eliminating the gray zone. What can be done in normal ALT values?].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():75. PubMed ID: 15373059
    [No Abstract]   [Full Text] [Related]  

  • 49. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C.
    Rakov NE
    N Engl J Med; 2003 Jan; 348(3):259-60; author reply 259-60. PubMed ID: 12529472
    [No Abstract]   [Full Text] [Related]  

  • 50. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treating hepatitis C: are children the same as adults?
    Delgado-Borrego A
    Gastroenterology; 2011 Feb; 140(2):389-92. PubMed ID: 21172331
    [No Abstract]   [Full Text] [Related]  

  • 52. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.
    Toyoda H; Kumada T
    Expert Opin Pharmacother; 2009 Dec; 10(17):2845-57. PubMed ID: 19891593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.
    Nayman Alpat S; Usluer G; Yavuz H; Doyuk Kartal E; Erben N; Bal C; Ozgunes I
    J Chemother; 2008 Feb; 20(1):101-5. PubMed ID: 18343751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The virological response in prolonged therapy of chronic hepatitis C with low-dose peginterferon alpha-2a].
    Zhou JY; Zhou DF; Xing WL; Zhao CY; Zhen Z
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Apr; 24(2):142-4. PubMed ID: 21110439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hepatitis C and HIV in Spanish prisons].
    Soriano V; González-Lahoz J
    Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):51-2. PubMed ID: 15743572
    [No Abstract]   [Full Text] [Related]  

  • 58. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
    Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.